The research company George Papanicolaou Hospital is conducting the clinical trial T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation (Penta-STs-001).
The purpose of the study is to determine the feasibility, safety and efficacy of administering rapidly-generated donor-derived pentavalent-specific T cells (Penta-STs) to mediate antiviral and antifungal activity in hematopoietic stem cell transplant (HSCT) recipients with AdV, EBV, CMV, BKV or Aspergillus fumigatus (AF) infection/ reactivation or with active disease.
It is planned to include 10 participants.
Actual study start date is January 24, 2022. The researchers expect to complete the study by April 30, 2023.
One primary outcome measure is Pathogen loads, The efficacy of penta-STs, which will be determined based on pathogen loads in patients.
Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT05471661.